This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Two out of four studies showed a significant reduction in depression risk with GLP-1 receptor agonists.
Why it matters
Understanding the potential mental health benefits of diabetes medications could improve patient care. Further research may lead to better treatment options for preventing depression in diabetic patients.
How the study worked
A systematic review of four retrospective observational studies on GLP-1 receptor agonists and depression risk in diabetes patients.
What this study cannot tell us
The study faced high interstudy heterogeneity, limited literature, and a lack of controlled trials.
Read the original research
Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic review.
Journal of psychiatric research, 164, 80-89
Citation
Cooper, Daniel H; Ramachandra, Ranuk; Ceban, Felicia; Di Vincenzo, Joshua D; Rhee, Taeho Greg; Mansur, Rodrigo B; Teopiz, Kayla M; Gill, Hartej; Ho, Roger; Cao, Bing; Lui, Leanna M W; Jawad, Muhammad Youshay; Arsenault, Juliet; Le, Gia Han; Ramachandra, Diluk; Guo, Ziji; McIntyre, Roger S. (2023). Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic review.. Journal of psychiatric research, 164, 80-89. https://doi.org/10.1016/j.jpsychires.2023.05.041